Radiation plus immunotherapy: a new hope for rectal cancer patients?
NCT ID NCT07394192
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new approach for people with stage II-III rectal cancer. It combines short-course radiotherapy that spares the tumor-draining lymph nodes with a PD-1 inhibitor (a type of immunotherapy). The goal is to see if this combination can lead to a complete disappearance of the cancer before surgery. The study will enroll 44 participants and is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
short-course radiotherapy and PD-1 inhibitor (pembrolizumab or similar)
What this could lead to
If successful, this approach could offer a more effective neoadjuvant therapy for rectal cancer, potentially increasing the chance of a complete response and reducing the need for more aggressive surgery.
What could go wrong
This is a small, early-phase exploratory study with only 44 participants. The combination therapy may not improve outcomes over standard treatment, and there are risks of side effects from both radiotherapy and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••